Tissue Antigens. 2004 Jan;63(1):28-33
Ehling R, Gassner C, Lutterotti A, Strasser-Fuchs S, Kollegger H, Kristoferitsch W, Reindl M, Berger T.
Department of Neurology, University of Innsbruck, Anichstrasse, Innsbruck, Austria, Central Institute for Blood Transfusion and Immunological Department, University Clinics, Anichstrasse, Innsbruck, Austria, Department of Neurology, University of Graz, Auenbruggerplatz, Graz, Austria, Department of Neurology, University of Vienna, Wahringer Gurtel, Vienna, Austria, Department of Neurology, SMZ Ost, Langobardenstrasse, Vienna, Austria.
Common genetic variants have been shown to influence disease susceptibility, disease course, or both in multiple sclerosis (MS).
Several studies have suggested a role for tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of MS.
Recently, it has been reported that the TNF receptor (TNFR) II plays an essential role in the pathology and progression of experimental autoimmune encephalomyelitis, an animal model of MS.
To investigate whether TNFR II polymorphisms influence susceptibility and/or clinical progression of MS, genomic DNA of 321 samples of the Austrian Genetics in MS study group and DNA of 174 platelet donors, who served as healthy controls, were genotyped for five polymorphic sites in the TNFR II gene: exon 6 nucleotide (nt) 676*T-->G, exon 6 nt 783*G-->A (both are associated with non-conserved amino acid substitution), exon 10 nt 1663*G-->A, exon 10 nt 1668*T-->G, and exon 10 nt 1690*T-->C (all of which are located in the 3' non-coding region of the gene).
We found a significant association between exon 10 nt 1668*T-->G polymorphism and susceptibility to MS.
The other investigated nucleotide substitutions were not associated with susceptibility to or clinical parameters in MS.